The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 8 June 2004, www.theannals.com, DOI 10.1345/aph.1D391.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1286-1292. DOI 10.1345/aph.1D391
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.

DRUG INFORMATION ROUNDS

OBJETIVO: Calcular la dosis equivalente aproximada de rosuvastatin comparado con otros inhibidores de la reductasa de hidroximetilglutaril-coenzima A en un programa de sustitución temporera.

EXTRACCIÓN DE DATOS: Ensayos clínicos que comparaban directamente rosuvastatin a otras estatinas como también evaluaban la magnitud de la disminución en colesterol.

SÍNTESIS DE DATOS: Se determinó los valores promedios de la lipoproteína de baja densidad y el colesterol total de ensayos clínicos. Los resultados de los estudios indican que no es equivalente a otras estatinas miligramo a miligramo.

CONCLUSIONES: Rosuvastatin parece ser al menos 2 y 4 veces más potente que atorvastatin y simvastatin, respectivamente, y al menos 8 veces más potente que pravastatin y lovastatin.

www.theannals.com


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
M. J. Pletcher, L. Lazar, K. Bibbins-Domingo, A. Moran, N. Rodondi, P. Coxson, J. Lightwood, L. Williams, and L. Goldman
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Ann Intern Med, February 17, 2009; 150(4): 243 - 254.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.